Clinical data
ATC code
  • none
  • (2S,4E)-5-(5-isopropoxypyridin-3-yl)-N-methylpent-4-en-2-amine
CAS Number
PubChem CID
Chemical and physical data
Molar mass234.343 g·mol−1
3D model (JSmol)
  • C[C@@H](C/C=C/C1=CC(=CN=C1)OC(C)C)NC
  • InChI=1S/C14H22N2O/c1-11(2)17-14-8-13(9-16-10-14)7-5-6-12(3)15-4/h5,7-12,15H,6H2,1-4H3/b7-5+/t12-/m0/s1 ☒N
 ☒NcheckY (what is this?)  (verify)

Ispronicline (TC-1734, AZD-3480) is an experimental drug which acts as a partial agonist at neural nicotinic acetylcholine receptors. It progressed to phase II clinical trials for the treatment of dementia and Alzheimer's disease, but is no longer under development.[1]

It has also progressed to phase II as a potential treatment for ADHD. With dosages of 50 mg/day showing a significant improvement in ADHD symptoms[2][3]

Ispronicline is subtype-selective, binding primarily to the α4β2 subtype. It has antidepressant, nootropic and neuroprotective effects.[medical citation needed]

Early stage clinical trials showed that ispronicline was well tolerated, with the main side effects being dizziness and headache.[4][5][6][7][8] However, mid-stage clinical trials failed to show sufficient efficacy to continue development as a pharmaceutical drug.[1]

See also


  1. ^ a b Armental M (14 July 2014). "Targacept Drops Development of Alzheimer's Drug". Wall Street Journal.
  2. ^ Potter AS, Dunbar G, Mazzulla E, Hosford D, Newhouse PA (February 2014). "AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit/hyperactivity disorder in adults". Biological Psychiatry. 75 (3): 207–214. doi:10.1016/j.biopsych.2013.06.002. PMID 23856296. S2CID 44717647.
  3. ^ AstraZeneca (2009-10-29). "An Exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD)". Targacept Inc.
  4. ^ Gatto GJ, Bohme GA, Caldwell WS, Letchworth SR, Traina VM, Obinu MC, et al. (2004). "TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects". CNS Drug Reviews. 10 (2): 147–166. doi:10.1111/j.1527-3458.2004.tb00010.x. PMC 6741718. PMID 15179444.
  5. ^ Dunbar G, Demazières A, Monreal A, Cisterni C, Metzger D, Kuchibhatla R, Luthringer R (July 2006). "Pharmacokinetics and safety profile of ispronicline (TC-1734), a new brain nicotinic receptor partial agonist, in young healthy male volunteers". Journal of Clinical Pharmacology. 46 (7): 715–726. doi:10.1177/0091270006288730. PMID 16809797. S2CID 22499622.
  6. ^ Lippiello P, Letchworth SR, Gatto GJ, Traina VM, Bencherif M (2006). "Ispronicline: a novel alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties". Journal of Molecular Neuroscience. 30 (1–2): 19–20. doi:10.1385/JMN:30:1:19. PMID 17192610.
  7. ^ Dunbar G, Boeijinga PH, Demazières A, Cisterni C, Kuchibhatla R, Wesnes K, Luthringer R (May 2007). "Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers". Psychopharmacology. 191 (4): 919–929. doi:10.1007/s00213-006-0675-x. PMID 17225162. S2CID 10920515.
  8. ^ Dunbar GC, Inglis F, Kuchibhatla R, Sharma T, Tomlinson M, Wamsley J (March 2007). "Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI)". Journal of Psychopharmacology. 21 (2): 171–178. doi:10.1177/0269881107066855. PMID 17329297. S2CID 10056476.